Zeytin H E, Tripathi P K, Bhattacharya-Chatterjee M, Foon K A, Chatterjee S K
Department of Microbiology and Immunology, University of Kentucky Medical Center, Lexington 45267, USA.
Cancer Gene Ther. 2000 Nov;7(11):1426-36. doi: 10.1038/sj.cgt.7700240.
Anti-idiotype antibody, 1A7, functionally mimics the tumor-associated antigen disialoganglioside GD2, which is overexpressed on the surface of a number of neuroectodermal tumors such as melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung. Immunization of mice with 1A7 generated the production of anti-GD2 antibodies. In a phase I clinical trial, immunization of patients with 1A7, mixed with the adjuvant QS21, demonstrated that 1A7 could act as a surrogate antigen for GD2 and induce strong humoral immune responses in advanced stage melanoma patients. DNA vaccines have recently been shown to invoke humoral as well as cellular responses in injected hosts against the transgene product. To evaluate the efficiency of DNA vaccines encoding anti-idiotype antibodies, we constructed expression plasmids encoding the variable heavy (VH) and variable light (VL) chains of 1A7. The plasmids were made in two configurations, expressing either the VH (pc1A7VHLnVL) or the VL (pc1A7VLLnVH) chain of 1A7 at the amino terminus, linked together by a 15-amino acid linker (Ln). In vitro transcription/translation assays and transfection of CHO-K1 cells with the plasmids demonstrated that a approximately 30-kDa protein was expressed by both configurations of the single-chain variable fragment. This protein can be specifically precipitated by monoclonal anti-GD2 antibody, 14G2a. Following intramuscular injection in mice, the plasmids were detectable in the injected tissues for at least 3 months and the injected plasmids actively transcribed the single-chain variable fragment 1A7 gene at the injected site. A single, intramuscular immunization of a group of C57BL/6 mice with pc1A7VLLnVH in phosphate-buffered saline induced humoral immune responses against 1A7 as well as GD2, the nominal antigen. Multiple immunizations, however, were required to elicit stronger immune responses.
抗独特型抗体1A7在功能上模拟肿瘤相关抗原双唾液酸神经节苷脂GD2,GD2在多种神经外胚层肿瘤表面过度表达,如黑色素瘤、神经母细胞瘤、软组织肉瘤和肺小细胞癌。用1A7免疫小鼠可产生抗GD2抗体。在一项I期临床试验中,用1A7与佐剂QS21混合免疫患者,结果表明1A7可作为GD2的替代抗原,并在晚期黑色素瘤患者中诱导强烈的体液免疫反应。最近研究表明,DNA疫苗可在注射宿主中引发针对转基因产物的体液免疫和细胞免疫反应。为了评估编码抗独特型抗体的DNA疫苗的效率,我们构建了编码1A7重链可变区(VH)和轻链可变区(VL)的表达质粒。这些质粒有两种构建形式,分别在氨基末端表达1A7的VH链(pc1A7VHLnVL)或VL链(pc1A7VLLnVH),通过一个15个氨基酸的接头(Ln)连接在一起。体外转录/翻译试验以及用这些质粒转染CHO-K1细胞表明,两种单链可变片段构建形式均表达了一种约30 kDa的蛋白质。该蛋白质可被单克隆抗GD2抗体14G2a特异性沉淀。在小鼠肌肉注射后,质粒在注射组织中至少可检测到3个月,且注射的质粒在注射部位积极转录单链可变片段1A7基因。用磷酸盐缓冲盐水中的pc1A7VLLnVH对一组C57BL/6小鼠进行单次肌肉免疫,可诱导针对1A7以及名义抗原GD2的体液免疫反应。然而,需要多次免疫才能引发更强的免疫反应。